Celera’s New Agreement With Laboratory Service (NASDAQ:CRA)

Berkeley HeartLab, a subsidiary of Celera Corporation (NASDAQ:CRA) announced today that they have entered into a collaborative agreements with Geisinger Medical Center and Proven Diagnostics, a clinical laboratory service launched by Geisinger Health System recently. Celera is a healthcare business focusing on the integration of genetic testing into routine clinical care through a combination of products and services incorporating proprietary discoveries. Berkeley HeartLab, a subsidiary of Celera, offers services to predict cardiovascular disease risk and improve patient management. Through this co-marketing agreement, Proven Diagnostics will provide selected diagnostic tools from BHL’s menu of proprietary cardiovascular tests and services which aims at optimizing cardiovascular treatment, these include BHL’s 4myheart cardiovascular disease management program as well.

@@CalendarRight@@ Proven Diagnostics is a new clinical diagnostic laboratory service provided by Geisinger Health System that is designed to provide medical professionals access to a wide array of clinical laboratory services. These services include microbiology, biochemical and hematology testing, esoteric genetic and allergy tests, and anatomical pathology. This new laboratory combines new and trusted technologies with outstanding customer service in support of physicians and their patients. These agreements were made under Proven Diagnostic’s Portfolio of Excellence program as they seek highly specialized laboratories to strengthen its growing menu of laboratory tests. In addition, Proven believes that agreements such as these help ensure that patients receive the most advanced cardiovascular laboratory testing.

Additionally, Proven Diagnostics and Geisinger Medical Center will be the first external clinical laboratories to have access to KIF6, BHL’s proprietary genetic test. The KIF6 gene encodes kinesin-like protein 6 (KIF6). This agreement allows Proven Diagnostics and Geisinger Medical Center to offer a more personal treatment approach for those with cardiovascular disease. Testing under the agreement will be performed by BHL. By combining Proven Diagnostics’ leading capabilities with the innovative content and services, such as KIF6 and 4myheart, BHL will provide a more personal approach to cardiovascular disease management.